Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
- Conditions
- Cervical CancerHuman Papillomavirus InfectionHuman Immunodeficiency VirusCervical DysplasiaGenital Warts
- Registration Number
- NCT06915779
- Lead Sponsor
- University of British Columbia
- Brief Summary
The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is determined by HIV parameters.
- Detailed Description
Study hypothesis: HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and that this decline will be determined by HIV parameters.
Girls and women living with HIV (greater than, or equal to, age 11) attending the HIV treatment clinics in each of the 13 sites across Canada and who enrolled in and received at least one dose of quadrivalent HPV vaccine as part of "A Study of an HPV VLP Vaccine in a Cohort of HIV Positive Girls and Women (CTN 236)" will be offered participation in this long term follow-up study.
OBJECTIVES
Primary:
To measure the antibody response to each genotype contained in the qHPV vaccine to 96 months post first dose of quadrivalent HPV vaccine.
Secondary:
1. To determine the incidence rate and nature of 'breakthrough' HPV incidence and persistent (2 sequential positive HPV DNA in \> 6 months) infections of vaccine - non-vaccine-containing high-risk types;
2. To determine the incidence rate of cervical dysplasia (LSIL or greater) and/or vulvar and vaginal dysplasia associated HPV genotypes (both with and without vaccine types; and
3. To determine the incidence rate of external genital warts.
Exploratory:
1. To examine the relationship between HSV-2 serostatus and peak HPV antibody response as well as HPV incidence and persistent infections; and
2. To relate vaginal microbiome profiles to HPV acquisition/persistence and cervical dysplasia.
STUDY DESIGN Phase 3, longitudinal, multi-center, 13 sites, girls and women living with HIV aged 11 years of age and older, received one plus dose of quadrivalent HPV vaccine in the precursor study.
STUDY VISITS 3 possible visits over a total of 5 years
* Visit 8 (month 36)
* Visit 9 (month 48)
* Visit 10 (month 60)
* Visit 11 (month 72)\*
* Visit 12 (month 84)\*
* Visit 13 (month 96)\*
STUDY PROCEDURES:
Informed consent, Medical history, Height \& weight, Cervical cytology and HPV DNA (liquid prep method), Gynecological swab for vaginal microbiota, Serology for HPV antibodies, Serology for HSV-2, Lower Urinary Tract Symptoms Survey (at one time-point only for participants 18 years of age and older).
NOTE: Girls who are pre-menarchal and not sexually active will not be asked to undergo any genital examinations or sampling until they become menarchal and sexually active.
DATA COLLECTION Consent and source document templates will be provided by the Study Coordinating Center. Source data will be transferred to paper case report forms and sent to the Study Coordinating Center/CTN where it will be entered into an electronic database.
PRIMARY ENDPOINT The primary endpoint of this study will be the HPV antibody GMT for each of the 4 types contained in the GARDASILâ„¢ vaccine up to month 96 after receiving at least one dose of the vaccine.
SECONDARY ENDPOINTS Incidence rates of: 1) breakthrough incidents and persistent HPV infections; 2) cervical dysplasia; 3) external genital warts
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 241
- Enrolled in CTN 236 study, phase 1
- Able to give fully informed consent or assent
- Did not receive at least one vaccination via CTN 236, phase 1
- Cannot provide fully informed consent or assent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Objective 96 month post-vaccination regimen To measure the antibody response to each genotype contained in the qHPV vaccine to 96 months post-vaccination regimen.
- Secondary Outcome Measures
Name Time Method Secondary Objective #1 96 month post-vaccination regimen To determine the incidence rate and nature of 'breakthrough' HPV incidence and persistent (2 sequential positive HPV DNA in \> 6 months) infections of vaccine - non-vaccine-containing high-risk types.
Secondary Objective #2 96 month post-vaccination regimen To determine the incidence rate of cervical dysplasia (LSIL or greater) and/or vulvar and vaginal dysplasia associated HPV genotypes (both with and without vaccine types
Secondary Objective #3 96 month post-vaccination regimen To determine the incidence rate of external genital warts.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (13)
Oak Tree Clinic, BC Women's Hospital & Health Centre
🇨🇦Vancouver, British Columbia, Canada
AIDS Research Program & the John Ruedy Immunodeficience Clinic, St. Paul's Hospital
🇨🇦Vancouver, British Columbia, Canada
Hamilton Health Sciences
🇨🇦Hamilton, Ontario, Canada
Infection & Immunology Clinic, Hotel Dieu
🇨🇦Kingston, Ontario, Canada
Children's Hospital of Eastern Ontario (CHEO)
🇨🇦Ottawa, Ontario, Canada
St. Michael's Hospital
🇨🇦Toronto, Ontario, Canada
The Hospital for Sick Children
🇨🇦Toronto, Ontario, Canada
Maple Leaf Research
🇨🇦Toronto, Ontario, Canada
Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
HIV Care Program
🇨🇦Windsor, Ontario, Canada
Centre de maternal et infantile sur le sida, CHU Sainte Justine
🇨🇦Montréal, Quebec, Canada
Chronic Viral Illness Service, Hopital Royal Victoria (McGill University)
🇨🇦Montréal, Quebec, Canada
CHUL and Mother-Child Center Soleil, Centre de Recherche en Infectiologie CHU de Quebec, (Universite Laval)
🇨🇦Québec City, Quebec, Canada